A5060206000- Sarcoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Soft tissue tumor case studies
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- Immune cells in cancer
- Soft tissue tumors and treatment
- Neurofibromatosis and Schwannoma Cases
- Genomics and Rare Diseases
- CAR-T cell therapy research
- Tumors and Oncological Cases
- RNA Interference and Gene Delivery
- Phytochemicals and Antioxidant Activities
- Ion Channels and Receptors
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Neuroblastoma Research and Treatments
- Cancer Cells and Metastasis
- Phagocytosis and Immune Regulation
- Pharmaceutical studies and practices
- Genetic Syndromes and Imprinting
- Pain Mechanisms and Treatments
- Advanced biosensing and bioanalysis techniques
- Cancer therapeutics and mechanisms
- Prenatal Screening and Diagnostics
Michigan State University
2021-2025
Cincinnati Children's Hospital Medical Center
2017-2021
University of Cincinnati Medical Center
2021
University of Cincinnati
2020
University of Michigan–Ann Arbor
2008
Developing novel strategies to overcome the immunosuppressive tumor microenvironment is a critically important area of cancer therapy research. Here, we assess therapeutic potential CD244 (2B4/signaling lymphocyte activation molecule family 4), an immunoregulatory receptor found on variety immune cells, including exhausted CD8
ABSTRACT Schinzel‐Giedion Syndrome (SGS) is an ultra‐rare, multisystem, genetic developmental disorder caused by gain‐of‐function pathogenic variants in the SETBP1 gene. No standard of care (SoC) recommendations currently exist. To assess expert opinion on SoC for individuals with SGS using a modified Delphi method. A multidisciplinary panel 21 experts from USA and Europe was assembled. Experts responded to two‐round questionnaire, subgroup participating virtual workshop, through which...
Abstract Chronic diabetic neuropathy is associated with peripheral demyelination and degeneration of nerve fibers. The mechanism(s) underlying neuronal injury in sensory remain poorly understood. Recently, we reported increased expression function transient receptor potential vanilloid 1 (TRPV1) large dorsal root ganglion (DRG) neurons neuropathy. In this study, examined the effects TRPV1 activation on cell pathways subpopulation streptozotocin‐induced rat model. Large DRG from (6–8 weeks)...
Abstract Background Desmoid tumors/aggressive fibromatosis (DT/AF) lack a reliably effective medical therapy. Surgical resection may be morbid and does not preclude recurrence. Radiation carry severe late effects, particularly detrimental in young patients. At our institution, we recently observed promising results with pazopanib therapy for DT/AF adolescent adult (AYA) Procedure Retrospective single‐institution chart review. Results Six patients of 3–21 years previously treated received...
Abstract Malignant peripheral nerve sheath tumor (MPNST) is a rare soft‐tissue sarcoma with an unfavorable prognosis and limited therapeutic options. MPNSTs can be sporadic, but are often associated neurofibromatosis (NF) 1 usually arise from preexisting neurofibromas. in patients NF2 have been reported only exceedingly cases, the mechanisms underlying transformation into MPNST not fully elucidated. Here, we describe clinicopathological genomic features of (PNST), primary diagnosis...
The US Food and Drug Administration-expanded access program (EAP) uses a single patient use (SPU) mechanism to provide investigational agents in situations where no satisfactory or comparable therapy is available. Genomic profiling of de novo relapsed refractory childhood cancer has led increased identification new drug targets the last decade. aim this study examine SPU experience for genomically targeted therapies patients with pediatric cancer.All therapeutic SPUs obtained over 5-year...
TPS7052 Background: Despite significant advances in therapy for acute myeloid leukemia (AML), 30-40% of young patients will relapse, after which prognosis is poor. In patients, curative-intent salvage involves intensive re-induction followed by hematopoietic stem cell transplant. Recently, the COG Phase II study CPX-351 (liposomal cytarabine:daunorubicin, Vyxeos™) pediatric with AML first relapse (NCT02642965) demonstrated a CR/CRi rate 81.3%. Separately, our first-in-pediatrics I...
10547 Background: There is a lack of reliably effective medical therapies for desmoid tumors (DT). Surgical resection may be morbid, and even complete does not preclude recurrence. Radiotherapy associated with potentially severe late-effects, risk that particularly detrimental in young patients. In previous review our single institution DT experience, we found objective treatment responses to were rare.However,we have recently observed promising effect from therapy the tyrosine kinase...
11514 Background: Contemporary chemotherapy-based regimens provide cures for most pediatric & AYA cancers. However, patients with relapsed/refractory malignancies, outcomes are poor imply a distinct and aggressive biology. Identifying common themes in the molecular architecture oncogenic mechanisms these is critical priority drug development. We hypothesized that signature of cancers would be independent histology. also assessed response to alteration (MA)-targeted therapies. Methods:...
Abstract Introduction: The Food and Drug Administration (FDA) expanded access program uses a single-patient use (SPU) mechanism to provide patient investigational agents prior FDA approval outside clinical trials, in situations where no satisfactory or comparable therapy is available. Genomic profiling of both newly diagnosed relapsed/refractory childhood cancer has increased the last decade, resulting identification new drug targets for pediatric malignancies. Recently, review SPU adult...